Share
Mark Rothera
TreeFrog Therapeutics, a French biotechnology company dedicated to scaling regenerative medicine through its proprietary C-Stem™ cell technology, has appointed Mark Rothera as Chief Executive Officer and Board Member.
His appointment marks an important leadership transition as the company enters its next phase of growth and clinical advancement.
Mr. Rothera succeeds Frédéric Desdouits, who is stepping down after five years as CEO, during which he played a key role in strengthening TreeFrog’s scientific foundation and strategic direction. As part of the new leadership structure, TreeFrog’s co-founders, Kévin Alessandri and Maxime Feyeux, will transition away from day-to-day operations to focus on their responsibilities as members of the Board of Directors, ensuring continued continuity and long-term vision.
Mark Rothera is a seasoned biotech executive with a strong track record of scaling innovative life sciences companies and advancing novel therapies from development through regulatory approval and commercialization. He has most recently held senior leadership roles at Viracta, Silence Therapeutics, and Orchard Therapeutics, where he was instrumental in building high-performing teams and guiding complex product portfolios.
Throughout his career, Mr. Rothera has focused on specialty diseases and advanced therapeutic modalities, including gene therapy and RNA interference (RNAi). Earlier in his career, he held commercial leadership positions at PTC Therapeutics, Aegerion, Shire, and GSK, gaining broad experience across global markets.
Mr. Rothera currently serves on the Board of GenPharm. He holds a Master of Arts in Natural Sciences from the University of Cambridge and an MBA from INSEAD. His leadership is expected to accelerate TreeFrog Therapeutics’ mission to bring regenerative medicine solutions to millions of patients worldwide.
